Recently, the recognition of NSCLC patients harboring EGFR mutations, who respond well to tyrosine kinase inhibitors (TKIs) like Gefitinib or Erlotinib, has revolutionized treatment plans, resulting in an improvement in clinical responses and quality of life. This evidence concerns the gene EGFR and non-small cell lung carcinoma.